Clinical Trials

Clinical Trial Detail

Return to search results.

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Complete title: A Proof-of-concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients with Merkel Cell Carcinoma

Research Study Number       8072
    
Principal Investigator       Shailender Bhatia, MD
    
Phase       I

Look up trial at NIH

Research Study Description

This is a single arm, open-label, single center study evaluating the safety, feasibility, clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell carcinoma. Ten patients will be treated. The goal is for GLA-SE to assist the patient's own immune system in attacking the cancer cells.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       8072
    
Contact       Mike Donahue
    
Telephone       206/288-7058
    
   

Keywords
Skin Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials